The global status and development trends of radioembolization for liver cancer with yttrium-90: a bibliometric analysis

Abstract

Abstract: Objective:To investigate the global status and development trends of radioembolization for liver cancer with yttrium-90 through bibliometric analysis.
Method:All available data of the articles concerning radioembolization for liver cancer with yttrium-90, based on Web of Science database from 1991 to 2021, were analyzed with bibliometric analysis for creating visual knowledge maps of the countries, institutions, authors, journals and keywords by VOS viewer.
Result:According to the search strategy and screening criteria, a total of 989 articles related to radioembolization for liver cancer with yttrium-90 were included in this study, involving 4 406 researchers from 1 055 institutions in 47 countries. The overall number of annual and cumulative publications significantly showed an upward trend, reaching a peak in 2021. United States dominated in national cooperation and number of articles. The top three institutions of total publications were Northwestern University, University of Navarra and Washington University. The top three authors of total publications and citations were Salem R, Lewandowski RJ and Mulcahy MF. Journal of Vascular and Interventional Radiology and other journals have played a vital role in promoting the development of this field. The top 10 keywords with occurrence frequency were radioembolization, hepatocellular carcinoma, yttrium-90, Y-90 microspheres, survival, cancer, liver metastases, microspheres, selective internal radiation therapy and internal radiation therapy.
Conclusion:Radioembolization for liver cancer with yttrium-90 is one of the important research hotspots of liver cancer. Chinese researchers should not only pay attention to the frontier research in this field, but also actively carry out multicenter clinical research projects.

Key words: Yttrium-90, Radioembolization, Selective internal radiation therapy, Liver cancer, Bibliometric analysis

Tang Fan, Luo Yingen, Ou Aixin, Xu Haoran, Li Xiao. The global status and development trends of radioembolization for liver cancer with yttrium-90: a bibliometric analysis[J]. Electronic Journal of Liver Tumor, 2023, 10(3): 38-47.

References

[1] SUNG H, FERLAY J, SIEGEL R L, et al.Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2] 中国临床肿瘤学会核医学专家委员会, 北京市核医学质量控制和改进中心. 钇-90(⁹⁰Y)微球选择性内放射治疗原发性和转移性肝癌的中国专家共识[J]. 中华肝脏病杂志, 2021, 29(7): 648-658.
[3] LEWANDOWSKI R J, GESCHWIND J F, LIAPI E, et al.Transcatheter intraarterial therapies: rationale and overview[J]. Radiology, 2011, 259(3): 641-657.
[4] SALEM R, GABR A, RIAZ A, et al.Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience[J]. Hepatology, 2018, 68(4): 1429-1440.
[5] MIOT H A, IANHEZ M, RAMOS P M.Trends in bibliometric indexes of the main dermatology journals (2009 to 2019)[J]. J Am Acad Dermatol, 2021, 85(3): 782-783.
[6] YU Q, TAN S, REN Y, et al.Bibliometric analysis of the 100 most-cited articles in the field of hepatology[J]. Gastroenterol Hepatol, 2020, 43(7): 349-357.
[7] SALEM R, LEWANDOWSKI R J, MULCAHY M F, et al.Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes[J]. Gastroenterology, 2010, 138(1): 52-64.
[8] WEBER M, LAM M, CHIESA C, et al.EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds[J]. Eur J Nucl Med Mol Imaging, 2022, 49(5): 1682-1699.
[9] O'DOHERTY J, SCUFFHAM J, HINTON P. The importance of scatter correction for the assessment of lung shunting prior to yttrium-90 radioembolization therapy[J]. Nucl Med Commun, 2011, 32(7): 628-634.
[10] BILBAO J I, GARRASTACHU P, HERRÁIZ M J, et al. Safety and efficacy assessment of flow redistribution by occlusion of intrahepatic vessels prior to radioembolization in the treatment of liver tumors[J]. Cardiovasc Intervent Radiol, 2010, 33(3): 523-531.
[11] CAMACHO J C, MONCAYO V, KOKABI N, et al.90Y Radioembolization: Multimodality Imaging Pattern Approach with Angiographic Correlation for Optimized Target Therapy Delivery[J]. Radiographics, 2015, 35(5): 1602-1618.
[12] TAFTI B A, PADIA S A.Dosimetry of Y-90 Microspheres Utilizing Tc-99m SPECT and Y-90 PET[J]. Semin Nucl Med, 2019, 49(3): 211-217.
[13] GULEC S A, MESOLORAS G, STABIN M.Dosimetric techniques in ⁹⁰Y-microsphere therapy of liver cancer: The MIRD equations for dose calculations[J]. J Nucl Med, 2006, 47(7): 1209-1211.
[14] RIAZ A, GATES V L, ATASSI B, et al.Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization[J]. Int J Radiat Oncol Biol Phys, 2011, 79(1): 163-171.
[15] KULIK L M, CARR B I, MULCAHY M F, et al.Safety and efficacy of ⁹⁰Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis[J]. Hepatology, 2008, 47(1): 71-81.
[16] SOMMA F, STOIA V, SERRA N, et al.Yttrium-90 trans-arterial radioembolization in advanced-stage HCC: The impact of portal vein thrombosis on survival[J]. PLoS One, 2019, 14(5): e0216935.
[17] VOUCHE M, HABIB A, WARD T J, et al.Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy[J]. Hepatology, 2014, 60(1): 192-201.
[18] LEWANDOWSKI R J, KULIK L M, RIAZ A, et al.A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization[J]. Am J Transplant, 2009, 9(8): 1920-1928.
[19] FERNÁNDEZ-ROS N, SILVA N, BILBAO J I, et al. Partial liver volume radioembolization induces hypertrophy in the spared hemiliver and no major signs of portal hypertension[J]. HPB (Oxford), 2014, 16(3): 243-249.
[20] SALEM R, GORDON A C, MOULI S, et al. Y90 Radioembolization Significantly Prolongs Time to Progression Compared with Chemoembolization in Patients with Hepatocellular Carcinoma[J]. Gastroenterology, 2016, 151(6): 1155-1163.e2.
[21] VILGRAIN V, PEREIRA H, ASSENAT E, et al.Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial[J]. Lancet Oncol, 2017, 18(12): 1624-1636.
[22] CHOW P K H, GANDHI M, TAN S B, et al. SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients with Hepatocellular Carcinoma[J]. J Clin Oncol, 2018, 36(19): 1913-1921.
[23] ALI R, RIAZ A, GABR A, et al.Clinical outcomes of Y90 radioembolization for recurrent hepatocellular carcinoma following curative resection[J]. Eur J Nucl Med Mol Imaging, 2017, 44(13): 2195-2202.
[24] IBRAHIM S M, MULCAHY M F, LEWANDOWSKI R J, et al.Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study[J]. Cancer, 2008, 113(8): 2119-2128.
[25] HOFFMANN R T, PAPROTTKA P M, SCHÖN A, et al. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival[J]. Cardiovasc Intervent Radiol, 2012, 35(1): 105-116.
[26] MOSCONI C, GRAMENZI A, ASCANIO S, et al.Yttrium-90 radioembolization for unresectable/recurrent intrahepatic cholangiocarcinoma: a survival, efficacy and safety study[J]. Br J Cancer, 2016, 115(3): 297-302.
[27] MULCAHY M F, MAHVASH A, PRACHT M, et al.Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, PhaseⅢ Trial[J]. J Clin Oncol, 2021, 39(35): 3897-3907.
[28] WASAN H S, GIBBS P, SHARMA N K, et al.First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials[J]. Lancet Oncol, 2017, 18(9): 1159-1171.
[29] CHENG B, SETHI I, DAVISSON N, et al.Yttrium-90 dosimetry and implications on tumour response and survival after radioembolisation of chemo-refractory hepatic metastases from breast cancer[J]. Nucl Med Commun, 2021, 42(4): 402-409.
[30] TSANG E S, LOREE J M, DAVIES J M, et al.Efficacy and Prognostic Factors for Y-90 Radioembolization (Y-90) in Metastatic Neuroendocrine Tumors with Liver Metastases[J]. Can J Gastroenterol Hepatol, 2020: 5104082.
[31] 颜志平, 林贵, 赵惠扬. 90钇玻璃微球内放射治疗原发性肝癌的初步临床应用[J]. 中华放射学杂志, 1994, (1): 55-57.
[32] ZU Q, SCHENNING R C, JAHANGIRI Y, et al.Yttrium-90 Radioembolization for BCLC Stage C Hepatocellular Carcinoma Comparing Child-Pugh A Versus B7 Patients: Are the Outcomes Equivalent?[J]. Cardiovasc Intervent Radiol, 2020, 43(5): 721-731.
[33] JIA Z, PAZ-FUMAGALLI R, FREY G T, et al.Prognostic factors in patients treated with transarterial radioembolization for unresectable and chemorefractory colorectal cancer with liver metastases[J]. Expert Rev Gastroenterol Hepatol, 2019, 13(9): 899-905.
[34] 牛惠敏, 王志恒, 高石鑫, 等. 钇90放射性微球在肝脏恶性肿瘤中的应用及进展[J/CD]. 肝癌电子杂志, 2021, 8(4): 36-40.
[35] 郑致远. 钇90放射性微球治疗肝脏恶性肿瘤的应用进展[J]. 复旦学报(医学版), 2020, 47(4): 622-627.